Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly.
作者信息
Sorscher Steven
机构信息
Retired Professor, Department of Medicine/Oncology Division, Wake Forest University School of Medicine, One Medical Center Blvd, Winston-Salem, USA.
出版信息
J Breast Cancer. 2022 Feb;26(1):86-91. doi: 10.4048/jbc.2022.25.e50. Epub 2022 Dec 5.
Abstract
摘要
相似文献
1
Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly.当新辅助使用曲妥珠单抗、帕妥珠单抗和帕博利珠单抗时可预测辅助治疗获益不明确的生物标志物。
J Breast Cancer. 2022 Feb;26(1):86-91. doi: 10.4048/jbc.2022.25.e50. Epub 2022 Dec 5.
2
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients.帕妥珠单抗与曲妥珠单抗生物类似药SB3双重抑制在HER2阳性乳腺癌患者中的安全性及临床评估
Breast Care (Basel). 2021 Dec;16(6):607-613. doi: 10.1159/000513766. Epub 2021 Feb 10.
3
Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.来自大学医院系统的真实世界证据，涉及 FDA 批准前和批准后辅助使用帕妥珠单抗和/或奈拉替尼的情况。
Breast Cancer Res Treat. 2021 Jun;187(3):883-891. doi: 10.1007/s10549-021-06132-8. Epub 2021 Feb 24.
4
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎症型或早期 HER2 阳性乳腺癌的疗效和安全性（NeoSphere）：一项随机、多中心、开放性、Ⅱ期临床试验。
Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.
5
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.APHINITY 试验中早期 HER2 阳性乳腺癌的辅助帕妥珠单抗和曲妥珠单抗治疗：6 年随访结果。
J Clin Oncol. 2021 May 1;39(13):1448-1457. doi: 10.1200/JCO.20.01204. Epub 2021 Feb 4.
6
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.NeoSphere研究的生物标志物分析：帕妥珠单抗、曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛、帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛用于HER2阳性乳腺癌新辅助治疗的比较
Breast Cancer Res. 2017 Feb 9;19(1):16. doi: 10.1186/s13058-017-0806-9.
7
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.曲妥珠单抗、帕妥珠单抗和化疗新辅助治疗与曲妥珠单抗恩美曲妥珠单抗和帕妥珠单抗联合用于 HER2 阳性乳腺癌患者（KRISTINE）：一项随机、开放标签、多中心、III 期临床试验。
Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.
8
Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.食管腺癌细胞和异种移植肿瘤暴露于表皮生长因子受体酪氨酸激酶 2 和 3 抑制剂可激活转化生长因子-β 信号通路，从而诱导上皮间质转化。
Gastroenterology. 2017 Jul;153(1):63-76.e14. doi: 10.1053/j.gastro.2017.03.004. Epub 2017 Mar 9.
9
Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study.帕妥珠单抗联合曲妥珠单抗辅助治疗人表皮生长因子受体 2 阳性早期乳腺癌：APHINITY 研究中中国患者的结局。
Jpn J Clin Oncol. 2021 Mar 3;51(3):345-353. doi: 10.1093/jjco/hyaa216.
10
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.帕妥珠单抗、曲妥珠单抗和多西他赛联合用于治疗人表皮生长因子受体 2（HER2）阳性转移性乳腺癌（CLEOPATRA）：一项双盲、随机、安慰剂对照、3 期研究的终期结果。
Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12.
本文引用的文献
1
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.ctDNA 检测在接受新辅助治疗的早期乳腺癌患者中的预后价值：系统评价和荟萃分析。
Cancer Treat Rev. 2022 Mar;104:102362. doi: 10.1016/j.ctrv.2022.102362. Epub 2022 Feb 18.
2
Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.循环肿瘤DNA作为接受新辅助治疗的II-III期乳腺癌患者复发的预测标志物。
Front Oncol. 2021 Nov 12;11:736769. doi: 10.3389/fonc.2021.736769. eCollection 2021.
3
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.APHINITY 试验中早期 HER2 阳性乳腺癌的辅助帕妥珠单抗和曲妥珠单抗治疗：6 年随访结果。
J Clin Oncol. 2021 May 1;39(13):1448-1457. doi: 10.1200/JCO.20.01204. Epub 2021 Feb 4.
4
Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint.定义肿瘤标志物检测的临床实用性：临床医生的观点。
J Clin Oncol. 2021 Jan 20;39(3):238-248. doi: 10.1200/JCO.20.01572. Epub 2020 Dec 16.
5
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.新辅助治疗乳腺癌患者循环肿瘤 DNA 可反映治疗应答和生存情况。
Ann Oncol. 2021 Feb;32(2):229-239. doi: 10.1016/j.annonc.2020.11.007. Epub 2020 Nov 21.
6
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.新辅助化疗后循环肿瘤 DNA 和循环肿瘤细胞与三阴性乳腺癌患者疾病复发的关系：BRE12-158 随机临床试验的预先计划的二次分析。
JAMA Oncol. 2020 Sep 1;6(9):1410-1415. doi: 10.1001/jamaoncol.2020.2295.
7
Neoadjuvant treatment for HER2-positive breast cancer.曲妥珠单抗辅助治疗 HER2 阳性乳腺癌的研究进展
Chin Clin Oncol. 2020 Jun;9(3):32. doi: 10.21037/cco-20-123. Epub 2020 Jun 3.
8
Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
9
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.个体化循环肿瘤 DNA 分析检测乳腺癌新辅助治疗后的残留病灶。
Sci Transl Med. 2019 Aug 7;11(504). doi: 10.1126/scitranslmed.aax7392.
10
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.曲妥珠单抗辅助治疗 HER2 阳性早期乳腺癌 6 个月与 12 个月的疗效对比（PERSEPHONE）：一项随机、III 期非劣效性试验的 4 年无病生存结果。
Lancet. 2019 Jun 29;393(10191):2599-2612. doi: 10.1016/S0140-6736(19)30650-6. Epub 2019 Jun 6.
Zotero 插件